Proactive Investors - Run By Investors For Investors

Creso Pharma and Virbac launches hemp‐based animal feed product in Switzerland

Virbac is one of the top 10 veterinary pharmaceutical companies in the world.
a plant
Anibidiol is a natural complementary feed

Creso Pharma Ltd (ASX:CPH) and Virbac SA (EPA:VIRP) have launched Anibidiol®, a hemp‐based complementary animal feed product in Switzerland.

Anibidiol is a natural complementary feed for companion animals containing a standardised amount of hemp extract with cannabidiol (CBD), the non-psychoactive substance of the hemp plant.

Creso has developed and will manufacture the product and Virbac will launch, market and promote it to veterinarians and pet owners.

Virbac is headquartered in France and is one of the top 10 veterinary pharmaceutical companies in the world.

Creso and Virbac had signed an agreement in September 2017, which will remain in effect for at least 3 years, in Switzerland and Lichtenstein.

Creso’s anibidiol®1.25 and anibidiol® 2.5 are designed for companion animals such as dogs and cats and come in proprietary granule formulations.

Anibidiol promotes the well-being of the animal by supporting its immunity and natural defence system. The product also supports the pet’s balanced behaviour.

The recession-resistant worldwide animal health market is valued at circa US$30 billion.

It is worth noting that 41% of pet owners have considered or tried various alternative therapies including nutritional supplements (29%) and herbal remedies (7%).

Creso’s share price increased circa 45% during the past one month, last closing at $0.80.

View full CPH profile View Profile

Related Articles

Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
1543827262_757z468_1542845960_Paradigm-cover.JPG
December 03 2018
The readout of clinical trials is expected this month.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use